Impact of Docetaxel and Dutasteride-Loaded Nanostructured Lipid Carriers on Male Rats: A Preclinical Evaluation

In this current investigation, we explored the impacts of Nanostructured Lipid Carriers (NLC) containing docetaxel (Dxt) and dutasteride (Dst) on male rats. Nanostructured lipid carriers (NLC) offer a promising drug delivery platform engineered to augment the efficacy of medications such as docetaxel (Dxt) and docetaxel (Dst) through a tailored production method. However, the potential acute toxicity administered Dxt-Dst NLC remains uncertain. Dxt-Dst-NLC was prepared by melt-emulsification and ultra-sonication techniques Male rats were administered DTX-DST NLC intravenously for 14 days. Throughout the treatment period, diligent observations were made regarding the rats' body weight and food consumption once the treatment concluded. On the 15th day, the rats were euthanized, and their hematological, biochemical, and histopathological profiles were evaluated. Dxt-Dst-NLC administered at 25 mg/kg caused liver damage observed in histopathological observations. Also, the elevation of SGOT and SGPT was observed. We observed inflammation at the injection site on the tail of these findings providing valuable insights that can serve as a foundation for further developing Dxt-Dst NLC as a potential therapeutic medication